Impact of C-arm CT in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transhepatic Arterial Chemoembolization (TACE): Optimal Imaging Guidance
Patients will be enrolled based on presence of HCC and eligibility for TACE. They will be randomized to one of two arms for imaging navigation to the optimal catheter location for chemotherapy injection to treat the first (possibly sole) tumor target. The two arms will be: TACE using C-arm CT supplemented by DSA or DSA only (only DSA images will be used for navigation and tumor vessel tracking). Navigation to subsequent treatment targets in all patients will be done with fluoroscopy, CACT, and DSA, as is standard of care at Stanford University Medical Center, and is not part of the study. Vascular complexity, which affects navigation difficulty and thus the need for imaging, will be assessed separately for use in data analysis by two radiologists on a four-point scale.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- Lawrence "Rusty" Hofmann, MD
- David Hovsepian, MD
- Gloria Hwang, MD
- John D. Louie, MD
- Daniel Sze, MD, PhD
- WILLIAM T. KUO, MD, FSIR, FCCP, FSVM, FCIRSE
- Nishita Kothary, MD
- device : DSA only
- device : C-arm CT + DSA as needed
Ages Eligible For Study:
Patients must be affected by HCC Patients must be 18 years old or older Patients must have received an abdominal CT, PET/CT scan or MRI, completed prior to the TACE procedure. Ability to understand and the willingness to sign a written informed consent document.